Back to Archived Journals » Research and Reports in Medicinal Chemistry » Volume 5

Pyrrolyl thiadiazoles as Mycobacterium tuberculosis inhibitors and their in silico analyses

Authors Joshi S, More U, Sorathiya S, Koli D, Aminabhavi T

Received 6 January 2015

Accepted for publication 12 February 2015

Published 28 April 2015 Volume 2015:5 Pages 1—20

DOI https://doi.org/10.2147/RRMC.S80395

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Xing-Cong Li


Shrinivas D Joshi,1 Uttam A More,1,2 Shailesh Sorathiya,1 Deepshikha Koli,1 Tejraj M Aminabhavi1

1Novel Drug Design and Discovery Laboratory, Department of Pharmaceutical Chemistry, Soniya Education Trust’s College of Pharmacy, Dharwad, India; 2Centre for Research and Development, Prist University, Thanjavur, Tamil Nadu, India

Abstract: A novel series of pyrrolyl thiadiazoles was synthesized and tested for antimycobacterial activity against the Mycobacterium tuberculosis H37Rv strain, using the microplate Alamar blue assay method. Molecular docking and in vitro minimum inhibitory concentration assays revealed that these molecules can be primarily screened for ENR inhibition, using the score values and H-bond interactions with amino acid residues Tyr158, Met98, and cofactor NAD+, which are the key interactions. For most of the molecules, hydrophobic interaction is the key factor affecting their antitubercular activity. The activity of -OCH3, -NO2, -F, pyridine, and sulfonamide substituted derivatives was better than that of -CH3, -NH2, -Cl, and -Br substituted derivatives, as per experimental and docking studies. Molecular modeling studies are in agreement with their biological evaluations.

Keywords: pyrroles, antitubercular activity, Surflex-Docking, enoyl-ACP reductase

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]